Navigation Links
PROLOR Biotech's Longer-Acting Human Growth Hormone Data Selected for Presentation at 5th International Congress Of The Growth Hormone Research Society and IGF Society
Date:9/27/2010

that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the CTP platform technology could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties.  In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in PROLOR's filings with the Securities and Exchange Commission.  The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.PROLOR CONTACT:

MEDIA CONTACT:Shai Novik, President

Barbara LindheimPROLOR Biotech, Inc.

GendeLLindheim BioCom PartnersTel: +1 866 644-7811

+1 212 918-4650Email: shai@prolor-biotech.com
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. PROLOR Biotech Awarded Two U.S. Patents for Its Longer-Acting Human Growth Hormone and Longer-Acting Erythropoietin
2. PROLOR Biotech Announces $10 Million Preferred Stock Line From Members of The Frost Group
3. PROLOR Biotech Acquires License Option from Yeda for Development of Long-Acting Anti-Obesity Drug
4. PROLOR Biotech to Present at the UBS 2009 Global Life Sciences Conference
5. PROLOR Biotech Announces Initiation of Phase I Clinical Trial for its Long-Acting Growth Hormone
6. Swedish-American Life Science Summit (SALSS) to Address Major Issues Including Healthcare Reform, Synthetic Biology and Innovative Financing for Biotechs
7. Modigene Awarded Second-Year Grant by Israeli Government to Support Development of Its Longer-Acting Human Growth Hormone
8. Thousands Rally in Mexico City and Call for Human Rights Protections in Global AIDS Response
9. DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
10. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
11. UC Riverside researcher develops novel method to grow human embryonic stem cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... August 28, 2014 SPIE Fellow Glenn ... and Optical Science and Director of the Center for ... Carolina at Charlotte, and co-founder and Chairman of the ... as the 2015 Vice President of SPIE, the international ... Philip Stahl announced recent election results at the Annual ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and ... 150 ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for ... owners and USDA-GIPSA inspection agencies that have a need to ... place in a matter of minutes with nothing but our ... feed and grain before accepting it, but they no longer ...
(Date:8/28/2014)... NEW YORK , Aug. ... announces that a new market ... its catalogue: Whole ... (Systems, Kits (Library Preparation, Target ... Technology (Sequencing by Synthesis), by ...
(Date:8/28/2014)... 2014   SunTrust Robinson Humphrey (STRH) ... to its equity research team in biotechnology and ... in equity research demonstrates our commitment to providing ... enhance their investment decision making," said Biff ... continue to make significant investments in differentiated content ...
Breaking Biology Technology:Glenn Boreman, UNC Professor and Plasmonics Co-Founder, Elected to SPIE Presidential Chain 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 2Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 3Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 4Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 5Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 6Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 7Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 8Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 9Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 10Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 11Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 12Whole Exome Sequencing Market by Product (Systems, Kits (Library Preparation, Target Enrichment), by Services (Sequencing), by Technology (Sequencing by Synthesis), by Application (Cancer, Monogenic disorders) - Global Forecast to 2018 13SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 2SunTrust Robinson Humphrey Expands Equity Research in Healthcare and Energy 3
... Corp. (IDC) announced today that Guy F. Cipriani, MBA ... Business Officer.  In the position, Mr. Cipriani will leverage ... experience to lead strategy and business development activities for ... and immunotherapies for infectious diseases, cancer and allergy. ...
... 17, 2011 Sutro Biopharma, a biopharmaceutical company ... pharmaceutical properties, today announced that the company,s proprietary ... and manufacturing of novel protein therapeutics will be ... Trevor Hallam, Ph.D., chief scientific officer ...
... report ,Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018, ... and expects it to grow at a compound annual growth rate ... billion by 2018. The depression therapeutics market ... 2013 and Effexor XR in 2014. However, the launch of new ...
Cached Biology Technology:Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer 2Sutro Biopharma to Present its Biochemical Protein Synthesis Technology at BioProduction Conference 2011 in Berlin 2ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018 2ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018 3ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018 4
(Date:8/28/2014)... that an expansion of marine protected areas is needed ... According to investigators from the Wildlife Conservation Society ... focused on saving the largest numbers of species, often ... and difficult-to-replace ecological functions. , Many vital ... species that also are food for millions of people. ...
(Date:8/28/2014)... A Mayo Clinic researcher and his collaborators have developed ... enhance the process of re-engineering cells for biomedical investigation. ... biology methods to aid stem cell engineering. Details of ... described in two back-to-back papers in the journal ... range of uses for all types of cell-based investigations ...
(Date:8/28/2014)... -- Scientists have identified the developmental on-off switch for ... produce more than two-thirds of the world,s naturally derived ... to see whether it is possible to manipulate this ... , The study, appearing August 28 in Cell ... molecule called cyclic-di-GMP and a larger protein called BldD ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2New tool aids stem cell engineering for medical research 2Small molecule acts as on-off switch for nature's antibiotic factory 2Small molecule acts as on-off switch for nature's antibiotic factory 3
... known as ovarian ,chocolate, cysts for the brown liquid ... recurrence is common, which can cause ongoing pain and ... a simple and effective remedy the oral contraceptive ... and Shelley Reilly from Auckland, New Zealand, highlight a ...
... that are helping fight a multi-front war on cancer may ... researchers said. Cancer and cardiovascular disease, both among top ... 90 inhibitors as a treatment could become additional common ground, ... "I think hsp90 inhibitors may be some of the ...
... the use of Chinese wolfberries to improve vision deficiencies that ... research assistant professor of human nutrition, is studying wolfberries and ... show that the fruit can lower the oxidative stress that ... "I would not say that wolfberries are a medicine, but ...
Cached Biology News:New cancer therapy may fight cardiovascular disease 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 2Study uses Chinese wolfberries to improve vision imperfections caused by type-2 diabetes 3